专家：晚期肺癌的治疗目标已经转向追求“延长生存”

Core Viewpoint - The treatment goal for late-stage lung cancer has shifted towards extending survival, with overall survival (OS) becoming the core clinical focus [2] Group 1: Early Detection and Treatment Advances - Increasing numbers of lung cancer patients are being detected early and receiving timely interventions, leading to improved five-year survival rates [1] - Innovative immunotherapy options are rapidly developing, providing long-term survival hope for late-stage lung cancer patients and moving towards early and mid-stage patients [1] - The early stage of lung cancer is identified as the "golden window" for treatment, where patients have the potential for clinical cure through radical surgery [1] Group 2: Post-Surgery Treatment and Management - Despite surgery, many patients face recurrence or metastasis risks, necessitating more effective adjuvant treatment methods [1] - The maturity of perioperative immunotherapy models has significantly improved patient prognosis, with multiple phase III clinical studies confirming reduced recurrence risks and increased five-year survival rates [1] Group 3: Late-Stage Lung Cancer Management - The application of immunotherapy has led to a historic breakthrough in the five-year survival rate for late-stage non-small cell lung cancer (NSCLC) patients [2] - In the small cell lung cancer (SCLC) field, immunotherapy combined with chemotherapy has shown long-term survival benefits in first-line treatment [2] - Late-stage lung cancer patients are gradually entering a chronic disease management phase, achieving longer and higher quality of life [2]